8 results on '"Morawski, Bozena M"'
Search Results
2. Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.
- Author
-
Montgomery, Martha P., Nakasujja, Noeline, Morawski, Bozena M., Rajasingham, Radha, Rhein, Joshua, Nalintya, Elizabeth, Williams, Darlisha A., Hullsiek, Kathy Huppler, Kiragga, Agnes, Rolfes, Melissa A., Carlson, Renee Donahue, Bahr, Nathan C., Birkenkamp, Kate E., Manabe, Yukari C., Bohjanen, Paul R., Kaplan, Jonathan E., Kambugu, Andrew, Meya, David B., Boulware, David R., and Huppler Hullsiek, Kathy
- Subjects
- *
COGNITION disorders , *HIV-positive persons , *CRYPTOCOCCALES , *ANTIGENS , *COHORT analysis , *NEUROPSYCHOLOGICAL tests , *MENINGITIS diagnosis , *HIV infection complications , *CRYPTOCOCCUS neoformans , *CRYPTOCOCCUS , *FUNGAL antigens , *LONGITUDINAL method , *RESEARCH funding , *DIAGNOSIS - Abstract
Background: HIV-infected persons with detectable cryptococcal antigen (CrAg) in blood have increased morbidity and mortality compared with HIV-infected persons who are CrAg-negative. This study examined neurocognitive function among persons with asymptomatic cryptococcal antigenemia.Methods: Participants from three prospective HIV cohorts underwent neurocognitive testing at the time of antiretroviral therapy (ART) initiation. Cohorts included persons with cryptococcal meningitis (N = 90), asymptomatic CrAg + (N = 87), and HIV-infected persons without central nervous system infection (N = 125). Z-scores for each neurocognitive test were calculated relative to an HIV-negative Ugandan population with a composite quantitative neurocognitive performance Z-score (QNPZ-8) created from eight tested domains. Neurocognitive function was measured pre-ART for all three cohorts and additionally after 4 weeks of ART (and 6 weeks of pre-emptive fluconazole) treatment among asymptomatic CrAg + participants.Results: Cryptococcal meningitis and asymptomatic CrAg + participants had lower median CD4 counts (17 and 26 cells/μL, respectively) than the HIV-infected control cohort (233 cells/μL) as well as lower Karnofsky performance status (60 and 70 vs. 90, respectively). The composite QNPZ-8 for asymptomatic CrAg + (-1.80 Z-score) fell between the cryptococcal meningitis cohort (-2.22 Z-score, P = 0.02) and HIV-infected controls (-1.36, P = 0.003). After four weeks of ART and six weeks of fluconazole, the asymptomatic CrAg + cohort neurocognitive performance improved (-1.0 Z-score, P < 0.001).Conclusion: Significant deficits in neurocognitive function were identified in asymptomatic CrAg + persons with advanced HIV/AIDS even without signs or sequelae of meningitis. Neurocognitive function in this group improves over time after initiation of pre-emptive fluconazole treatment and ART, but short term adherence support may be necessary. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
3. Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis.
- Author
-
Lofgren, Sarah, Hullsiek, Kathy H., Morawski, Bozena M., Nabeta, Henry W., Kiggundu, Reuben, Taseera, Kabanda, Musubire, Abdu, Schutz, Charlotte, Abassi, Mahsa, Bahr, Nathan C., Tugume, Lillian, Muzoora, Conrad, Williams, Darlisha A., Rolfes, Melissa A., Velamakanni, Sruti S., Rajasingham, Radha, Meintjes, Graeme, Rhein, Joshua, Meya, David B., and Boulware, David R.
- Subjects
- *
MENINGITIS , *CRYPTOCOCCALES , *CYTOKINES , *IMMUNOLOGY , *PATHOLOGICAL psychology , *MENTAL status examination , *PATIENTS , *ANTIFUNGAL agents , *CHEMOKINES , *COMPARATIVE studies , *CRYPTOCOCCUS neoformans , *CRYPTOCOCCUS , *FUNGAL antigens , *INTERLEUKINS , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MENTAL illness , *RESEARCH , *RESEARCH funding , *PILOT projects , *EVALUATION research , *RANDOMIZED controlled trials , *PROPORTIONAL hazards models , *GLASGOW Coma Scale ,RISK factors - Abstract
Altered mental status in cryptococcal meningitis results in poorer survival, but underlying causes of altered mentation are poorly understood. Within two clinical trials, we assessed risk factors for altered mental status (GCS score<15) considering baseline clinical characteristics, CSF cytokines/chemokines, and antiretroviral therapy. Among 326 enrolled participants, 97 (30%) had GCS<15 and these patients had lower median CSF cryptococcal antigen titers (P = .042) and CCL2 (P = .005) but higher opening pressures (320 vs. 269 mm H2O; P = .016), IL-10 (P = .044), and CCL3 (P = .008) compared with persons with GCS=15. Altered mental status may be associated with host immune response rather than Cryptococcus burden. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Recurrence of Symptoms Following Cryptococcal Meningitis: Characterizing a Diagnostic Conundrum With Multiple Etiologies.
- Author
-
Bahr, Nathan C, Skipper, Caleb P, Huppler-Hullsiek, Kathy, Ssebambulidde, Kenneth, Morawski, Bozena M, Engen, Nicole W, Nuwagira, Edwin, Quinn, Carson M, Ramachandran, Prashanth S, Evans, Emily E, Lofgren, Sarah M, Abassi, Mahsa, Muzoora, Conrad, Wilson, Michael R, Meya, David B, Rhein, Joshua, and Boulware, David R
- Subjects
- *
CEREBROSPINAL fluid examination , *KRUSKAL-Wallis Test , *CD4 antigen , *RETROSPECTIVE studies , *DISEASE relapse , *HIGHLY active antiretroviral therapy , *CRYPTOCOCCUS neoformans , *IMMUNE reconstitution inflammatory syndrome , *CHI-squared test , *MENINGITIS , *SYMPTOMS - Abstract
Background Cryptococcal meningitis is a common cause of AIDS-related mortality. Although symptom recurrence after initial treatment is common, the etiology is often difficult to decipher. We sought to summarize characteristics, etiologies, and outcomes among persons with second-episode symptomatic recurrence. Methods We prospectively enrolled Ugandans with cryptococcal meningitis and obtained patient characteristics, antiretroviral therapy (ART) and cryptococcosis histories, clinical outcomes, and cerebrospinal fluid (CSF) analysis results. We independently adjudicated cases of second-episode meningitis to categorize patients as (1) microbiological relapse, (2) paradoxical immune reconstitution inflammatory syndrome (IRIS), (3) persistent elevated intracranial pressure (ICP) only, or (4) persistent symptoms only, along with controls of primary cryptococcal meningitis. We compared groups with chi-square or Kruskal-Wallis tests as appropriate. Results 724 participants were included (n = 607 primary episode, 81 relapse, 28 paradoxical IRIS, 2 persistently elevated ICP, 6 persistent symptoms). Participants with culture-positive relapse had lower CD4 (25 cells/μL; IQR: 9–76) and lower CSF white blood cell (WBC; 4 cells/μL; IQR: 4–85) counts than paradoxical IRIS (CD4: 78 cells/μL; IQR: 47–142; WBC: 45 cells/μL; IQR: 8–128). Among those with CSF WBC <5 cells/μL, 86% (43/50) had relapse. Among those with CD4 counts <50 cells/μL, 91% (39/43) had relapse. Eighteen-week mortality (from current symptom onset) was 47% among first episodes of cryptococcal meningitis, 31% in culture-positive relapses, and 14% in paradoxical IRIS. Conclusions Poor immune reconstitution was noted more often in relapse than IRIS as evidenced by lower CSF WBC and blood CD4 counts. These easily obtained laboratory values should prompt initiation of antifungal treatment while awaiting culture results. Clinical Trials Registration NCT01802385. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.
- Author
-
Pullen, Matthew F, Hullsiek, Katherine Huppler, Rhein, Joshua, Musubire, Abdu K, Tugume, Lillian, Nuwagira, Edwin, Abassi, Mahsa, Ssebambulidde, Kenneth, Mpoza, Edward, Kiggundu, Ruben, Akampurira, Andrew, Nabeta, Henry W, Schutz, Charlotte, Evans, Emily E, Rajasingham, Radha, Skipper, Caleb P, Pastick, Katelyn A, Williams, Darlisha A, Morawski, Bozena M, and Bangdiwala, Ananta S
- Subjects
- *
CEREBROSPINAL fluid examination , *AMPHOTERICIN B , *ANTIFUNGAL agents , *CLINICAL trials , *CRYPTOCOCCUS neoformans , *CULTURES (Biology) , *FUNGI , *MENINGITIS , *REGRESSION analysis , *SURVIVAL , *SECONDARY analysis , *PROPORTIONAL hazards models , *DESCRIPTIVE statistics , *FLUCONAZOLE , *COLONY-forming units assay , *PHARMACODYNAMICS - Abstract
Background In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA) of Cryptococcus clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint for all-cause mortality. The Food and Drug Administration allows for using surrogate endpoints for accelerated regulatory approval, but EFA as a surrogate endpoint requires further validation. We examined the relationship between rate of CSF Cryptococcus clearance (EFA) and mortality through 18 weeks. Methods We pooled individual-level CSF data from 3 sequential cryptococcal meningitis clinical trials conducted during 2010–2017. All 738 subjects received amphotericin + fluconazole induction therapy and had serial quantitative CSF cultures. The log10-transformed colony-forming units (CFUs) per mL CSF were analyzed by general linear regression versus day of culture over the first 10 days. Results Mortality through 18 weeks was 37% for EFA > = 0.60 (n = 170), 36% for 0.40–0.59 (n = 182), 39% for 0.30–0.39 (n = 112), 35% for 0.20–0.29 (n = 87), and 50% for those with EFA < 0.20 CFU/mL/day (n = 187). The hazard ratio for 18-week mortality, comparing those with EFA < 0.20 to those with EFA > = 0.20, was 1.60 (95% confidence interval, 1.25, 2.04; P = .002). The lowest EFA group had lower median CD4 T-cell counts (P < .01) and lower proportion of patients with CSF pleocytosis (P < .001). Conclusions EFA is associated with all-cause mortality in cryptococcal meningitis. An EFA threshold of > = 0.20 log10 CFU/mL/day was associated with similar 18-week mortality (37%) compared to 50% mortality with EFA < 0.20. This EFA threshold may be considered a target for a surrogate endpoint. This builds upon existing studies to validate EFA as a surrogate endpoint. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
- Author
-
Meya, David B., Kiragga, Agnes N., Nalintya, Elizabeth, Morawski, Bozena M., Rajasingham, Radha, Park, Benjamin J., Mubiru, Anthony, Kaplan, Jonathan E., Manabe, Yukari C., and Boulware, David R.
- Abstract
Supplemental Digital Content is Available in the Text. Background: HIV-infected persons with cryptococcal antigenemia (CrAg) are at high risk for meningitis or death. We evaluated the effect of CrAg screening and preemptive fluconazole therapy, adjunctive to antiretroviral therapy (ART), on 6-month survival among persons with advanced HIV/AIDS. Methods: We enrolled HIV-infected, ART-naive participants with <100 CD4 cells/µL, in a stepped-wedge, cluster-randomized trial from July 2012 to December 2014 at 17 Ugandan clinics. Clinics participated in a prospective observational phase, followed by an interventional phase with laboratory-based, reflexive CrAg screening of residual CD4 count plasma. Asymptomatic CrAg+ participants received preemptive fluconazole therapy. We assessed 6-month survival using Cox-regression, adjusting for nadir CD4, calendar time, and stepped-wedge steps. Results: We included 1280 observational and 2108 interventional participants, of whom 9.3% (195/2108) were CrAg+. CD4-, time-, and stepped-wedge–adjusted analyses demonstrated no difference in survival in the observational vs the interventional arms (hazard ratio = 1.34; 95% confidence interval: 0.86 to 2.10; P = 0.20). Fewer participants initiated ART in the interventional (73%) versus the observational phase (82%, P < 0.001). When ART initiation was modeled as a time-dependent covariate or confounder, survival did not differ. However, 6-month mortality of participants with CrAg titers <1:160 and CrAg-negative patients did not differ. Patients with CrAg titers ≥1:160 had 2.6-fold higher 6-month mortality than patients with titers <1:160. Conclusions: We observed no overall survival benefit of the CrAg screen-and-treat intervention. However, preemptive antifungal therapy for asymptomatic cryptococcosis seemed to be effective in patients with CrAg titer <1:160. A more aggressive approach is required for persons with CrAg titer ≥1:160. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006-2016.
- Author
-
Flynn, Andrew G., Meya, David B., Hullsiek, Katherine Huppler, Rhein, Joshua, Williams, Darlisha A., Musubire, Abdu, Morawski, Bozena M., Taseera, Kabanda, Sadiq, Alisat, Ndyatunga, Liberica, Roediger, Mollie, Rajasingham, Radha, Bohjanen, Paul R., Muzoora, Conrad, and Boulware, David R.
- Subjects
- *
HIV infections , *THERAPEUTICS , *MENINGITIS , *HIGHLY active antiretroviral therapy - Abstract
Background. Because of investments in human immunodeficiency virus (HIV) care in sub-Saharan Africa, the number of people aware of their status and receiving antiretroviral therapy (ART) has increased; however, HIV/acquired immune deficiency syndrome (AIDS) mortality still remains high. Methods. We performed retrospective analysis of 3 sequential prospective cohorts of HIV-infected Ugandan adults presenting with AIDS and meningitis from 2006 to 2009, 2010 to 2012, and 2013 to 2016. Participants were categorized as follows: (1) unknown HIV status; (2) known HIV+ without ART; (3) known HIV+ with previous ART. We further categorized 2006 and 2013 cohort participants by duration of HIV-status knowledge and of ART receipt. Results. We screened 1353 persons with suspected meningitis. Cryptococcus was the most common pathogen (63%). Over the decade, we observed an absolute increase of 37% in HIV status knowledge and 59% in antecedent ART receipt at screening. The 2006 cohort participants were new/recent HIV diagnoses (65%) or known HIV+ but not receiving ART (35%). Many 2013 cohort participants were new/recent HIV diagnoses (34%) and known HIV+ with <1 month ART (20%), but a significant proportion were receiving ART 1-4 months (11%) and >4 months (30%). Four percent of participants discontinued ART. From 2010 to 2016, meningitis cases per month increased by 33%. Conclusions. Although improved HIV screening and ART access remain much-needed interventions in resource-limited settings, greater investment in viral suppression and opportunistic infection care among the growing HIV-infected population receiving ART is essential to reducing ongoing AIDS mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis.
- Author
-
Rhein, Joshua, Bahr, Nathan C., Morawski, Bozena M., Schutz, Charlotte, Zhang, Yonglong, Finkelman, Malcolm, Meya, David B., Meintjes, Graeme, and Boulware, David R.
- Subjects
- *
CEREBROSPINAL fluid , *GLUCANS , *HIV infections , *HIV-positive persons , *CRYPTOCOCCOSIS - Abstract
(1→3)-Beta-D-glucan was detected in high levels in cerebrospinal fluid, and to lesser extent in serum, among HIV-infected persons with cryptococcal meningitis.Background. (1→3)-β-d-Glucan (BDG) is a helpful diagnostic marker for many invasive fungal infections. However, BDG is not thought to be useful in diagnosing cryptococcosis. We evaluated the utility of BDG as an adjunct diagnostic tool for patients infected with human immunodeficiency virus (HIV) and presenting with suspected cryptococcal meningitis.Methods. The Fungitell assay was used to measure BDG concentrations in cerebrospinal fluid (CSF) (n = 177) and serum (n = 109) of HIV-infected Ugandans and South Africans with suspected meningitis. Correlations between BDG concentrations and quantitative CSF cryptococcal cultures, CSF cryptococcal antigen (CRAG) titers, and 18 different CSF cytokine concentrations were assessed using non-parametric tests. Mixed models evaluated longitudinal changes in CSF BDG concentrations. Survival analyses were used to evaluate BDG's relationship with mortality.Results. The Fungitell BDG assay provided 89% sensitivity and 85% specificity in CSF for cryptococcal meningitis. Serum sensitivity was suboptimal (79%). Cerebrospinal fluid BDG concentrations at diagnosis were median (interquartile range) 343 (200–597) pg/mL in cryptococcal patients and 37 (23–46) pg/mL in patients without cryptococcosis. Sensitivity in CSF improved to 98% (53 of 54) when initial fungal burdens were ≥10 000 colony-forming units/mL. (1→3)-β-d-Glucan normalized rapidly after initiating antifungal therapy. Baseline BDG concentrations correlated with CSF fungal burden (rho = 0.820; P < .001), CSF CRAG lateral flow assay titers (rho = 0.780, P < .001), and monocyte chemotactic protein-1 levels in CSF (P = .047). In patients with cryptococcal meningitis, BDG ≥500 pg/mL at diagnosis was associated with increased 10-week mortality.Conclusions. (1→3)-β-d-Glucan is detectable in the CSF of HIV-infected patients with Cryptococcus, and it may provide useful prognostic information. Sensitivity is less than CRAG; however, BDG normalizes rapidly, unlike CRAG, making BDG potentially useful in diagnosing recurrent episodes. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.